Clinicopathogenomic analysis of PI3K/AKT/PTEN-altered luminal metastatic breast cancer in Japan
Breast Cancer · 2025
DOI: 10.1007/s12282-024-01639-6 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Breast Cancer, 2025. Verfasst von Hiroshi Tada und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Endocrine Surgical Oncology, Graduate School of Medicine, Tohoku University, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-…. Hauptthemen laut MEDLINE: Breast Neoplasms, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This rapid communication highlights the correlation between protein kinase B alpha ( AKT1 )-phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha ( PIK3CA )- phosphatase and tensin homolog ( PTEN ) alterations and clinicopathological factors in Japanese patients with metastatic recurrent breast cancer (mBC). This study analyzed 1967 patients with luminal-type breast cancer who underwent cancer gene panel testing. The results demonstrated that AKT pathway alterations, including PI3K/AKT/PTEN , occurred in 1038 (52.8%) cases. Patients with AKT pathway mutations were older (p = 0.002) and had a higher rate of invasive lobular carcinoma (ILC) histology (p = 0.001), progesterone receptor (PgR) positivity (p = 0.006), and bone metastases (p = 0.001), and a lower rate of germline BRCA2 (p < 0.001). Comprehensive genomic profile results demonstrated a higher tumor mutational burden (TMB) (< 0.001) and lower tumor BRCA1/2 expression (< 0.001) in patients with mutations in the AKT pathway. These results are crucial for characterizing candidates for AKT pathway-targeted molecular therapies and conceptualizing optimal treatment strategies. Clinical trial registration: This study is an observational study and is therefore not registered with the clinical trials registration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast and Endocrine Surgical Oncology, Graduate School of Medicine, Tohoku University, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan. hiroshi.tada.a4@tohoku.ac.jp.
- Department of Breast and Endocrine Surgical Oncology, Graduate School of Medicine, Tohoku University, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.
Zitieren
APA
Tada, H., Miyashita, M., Harada-Shoji, N., Ebata, A., Sato, M., Motonari, T., Yanagaki, M., Kon, T., Sakamoto, A., & Ishida, T. (2025). Clinicopathogenomic analysis of PI3K/AKT/PTEN-altered luminal metastatic breast cancer in Japan. Breast Cancer. https://doi.org/10.1007/s12282-024-01639-6
Vancouver
Tada H, Miyashita M, Harada-Shoji N, Ebata A, Sato M, Motonari T, et al. Clinicopathogenomic analysis of PI3K/AKT/PTEN-altered luminal metastatic breast cancer in Japan. Breast Cancer. 2025. doi:10.1007/s12282-024-01639-6
BibTeX
@article{Tada2025,
author = {Tada, Hiroshi and Miyashita, Minoru and Harada-Shoji, Narumi and Ebata, Akiko and Sato, Miku and Motonari, Tokiwa and Yanagaki, Mika and Kon, Tomomi and Sakamoto, Aru and Ishida, Takanori},
title = {Clinicopathogenomic analysis of PI3K/AKT/PTEN-altered luminal metastatic breast cancer in Japan},
journal = {Breast Cancer},
year = {2025},
doi = {10.1007/s12282-024-01639-6}
}
EUVIMED